Posts

Posted on

Andersen Announces Pricing of Secondary Offering

Andersen Announces Pricing of Secondary Offering

SAN FRANCISCO–(BUSINESS WIRE)–
Andersen Group Inc. (NYSE: ANDG), a leading independent provider of tax, valuation and financial advisory services to individuals, family offices, businesses and alternative investment funds in the United States, today announced the pricing of an underwritten public offering of 4,284,457 shares of its Class A common stock by certain selling stockholders at a public offering price of $44.00 per share. Gross proceeds to the selling stockholders are expected to be approximately $188.5 million, before underwriting discounts and commissions and other offering expenses. The selling stockholders have also granted the underwriters a 30-day option to purchase up to an additional 642,668 shares of Class A common stock at the public offering price, less underwriting discounts and commissions. Andersen is not selling any shares in the offering and will not receive any proceeds from the sale of shares by the selling stockholders. The offering is expected to close on August 21, 2026, subject to customary closing conditions.

Baird, Truist Securities and UBS Investment Bank are serving as lead book-running managers with William Blair acting as additional book-running manager.

The offering is being made only by means of a prospectus. Copies of the prospectus relating to this offering are available from:

  • Robert W. Baird & Co. Incorporated, Attention: Syndicate Department, 777 E. Wisconsin Avenue, Milwaukee, Wisconsin 53202; phone: (800) 792-2473; email: [email protected];
  • Truist Securities, Inc., Attention: Equity Capital Markets, 740 Battery Ave SE, 3rd Floor, Atlanta, Georgia 30339; phone: (800) 685-4786; email: [email protected];
  • UBS Securities LLC, Attention: Prospectus Department, 11 Madison Avenue, New York, New York 10010; email: [email protected].

A registration statement relating to these securities has been filed with the Securities and Exchange Commission (“SEC”) and was declared effective on August 19, 2026. This press release does not constitute an offer to sell or a solicitation of an offer to buy these securities, and there shall be no sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under that state’s or jurisdiction’s securities laws.

About Andersen

Andersen is a leading provider of independent tax, valuation and financial advisory services to individuals, family offices, businesses and alternative investment funds in the United States. Andersen’s differentiated approach to client service is rooted in core values that emphasize stewardship, transparency and the seamless delivery of independent, high-quality service. Worldwide, Andersen’s presence spans more than 180 countries through its global platform of member and collaborating firms delivering tax, legal, valuation and consulting services across more than 1,000 locations with over 3,000 partners and 50,000 professionals.

Gregory Vistica, Managing Director, Investor Relations

[email protected]

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Legal Personal Finance Finance Asset Management Consulting Small Business Professional Services Business

MEDIA:

Logo
Logo
Posted on

Telix 2026 Half-Year Results: Strong Commercial Execution and Momentum in Late-Stage Pipeline

MELBOURNE, Australia and INDIANAPOLIS, Aug. 20, 2026 (GLOBE NEWSWIRE) — Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces its financial results for the period ended June 30, 2026.

H1 2026 key results

Group performance

1

: Double-digit revenue growth and gross margin improvement

  • Group revenue of US$477 million, up 22%2 year-over-year, tracking in line with the upper end of full year guidance of US$950 million to US$970 million.
  • Group gross margin of 55%, up 2% year-over-year, Precision Medicine gross margin of 65%, up 1% year-over-year, reflecting solid commercial performance, a favorable product mix and operational efficiencies.
  • Adjusted EBITDA3 of US$52 million, up 146% year-over-year reflecting strong demand across our product portfolio and initial non-refundable payment of US$40 million from Regeneron collaboration4.
  • Research & Development (R&D) investment of US$124 million, primarily directed toward advancing late-stage therapeutic and precision medicine programs, supporting the Company’s strategy to build diversified revenue streams.
  • Entered into strategic collaboration with Regeneron to jointly develop and commercialize next generation radiopharmaceutical therapies4.
  • Completed refinancing of existing convertible bond structure, issuing US$600 million of new convertible bonds due 20315.
  • Profit after tax of US$38 million includes US$40 million of other income received from Regeneron and finance costs of US$19 million, predominately related to refinancing of the convertible bonds.
  • Generated positive operating cash flow of US$23 million and maintained a cash balance of US$252 million as of June 30, 2026.

Executive commentary

Managing Director and Group CEO, Dr. Christian Behrenbruch, stated: “Telix delivered an outstanding first half, with strong revenue growth, market share gains and significant progress across clinical and regulatory milestones. Our strengthened balance sheet is enabling increased investment in late-stage programs, including ProstACT Global, market expansion opportunities within our precision medicine portfolio and manufacturing and supply chain capabilities that differentiate Telix. With multiple near-term catalysts, we enter the second half with strong momentum and confidence.”

Segment results

Telix Precision Medicine: Strong volume growth of Illuccix® and Gozellix®

  • Precision Medicine segment revenue up by 27% year-over-year reflecting continued success of Telix’s two product strategy, with Illuccix® and Gozellix® delivering growth in sales volumes and market share gains.
  • Gross margin of 65% up 1% year-over-year.
  • Adjusted (segment) EBITDA up by 26% year-over-year to US$132 million.
  • Patient enrollment nearing completion for Phase 3 BiPASS™ study of Illuccix and Gozellix for prostate cancer imaging in the pre-biopsy setting.
  • Illuccix Japan Phase 3 registrational study enrollment completion6.
  • New drug application (NDA) for Illuccix accepted and under review by the Chinese National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE)7.
  • TLX101-Px, (floretyrosine F 18) for glioma (brain cancer) imaging:
    • Pixclara®8 has been granted a PDUFA9 goal date by the FDA of September 11, 202610.
    • Pixlumi®8 Marketing Authorization Application (MAA) in Europe validated and accepted for review11.
    • Pixclara8 Phase 3 Investigational New Drug (IND) application successfully cleared by FDA to explore indication expansion to brain metastases diagnosis.
  • TLX250-Px, Zircaix®8 (zirconium-89 (89Zr) girentuximab senvedoxam) for kidney cancer imaging: Telix continues to make good progress toward near-term resubmission of its U.S. Biologics License Application (BLA). The Company has been granted an extension of the BLA resubmission deadline, following receipt of a corrected Complete Response Letter (CRL)12. Telix continues to work closely with the FDA to ensure the resubmission package comprehensively addresses all outstanding CRL items.

Telix Therapeutics: Investment delivering significant advances across a number of key late-stage development programs

Of the R&D investment, US$68 million was invested in the therapeutics pipeline. Milestones include:

  • TLX591-Tx (lutetium (

    177

    Lu) rosopatamab tetraxetan):

    • ProstACT Global Part 1 lead-in for Telix’s lead prostate cancer therapy candidate in metastatic castration-resistant prostate cancer (mCRPC) met safety and dosimetry objectives, with no new safety signals observed13.
    • FDA confirmed that the safety data from Part 1 is sufficient to enable progression of Part 2 in the U.S. The FDA and Telix also achieved alignment on the Part 2 clinical trial protocol14.
    • Part 2 continues to enroll well in regions where recruitment is open including Australia, Canada, New Zealand, Singapore, South Korea, Türkiye and the United Kingdom.
  • TLX597-Tx (

    177

    Lu-DOTA-HYNIC-panPSMA):

    • OPTIMAL-PSMA Phase 2 investigator-initiated trial (IIT) evaluating TLX597-Tx for mCRPC completed patient enrollment of 120 patients15.
    • OPTIMAL-e Phase 2 study evaluating TLX597-Tx for metastatic hormone sensitive prostate cancer (mHSPC) dosed first patients16.
  • TLX250-Tx (lutetium (

    177

    Lu) girentuximab tetraxetan):

    • Dosed first patient in LUTEON, a pivotal trial of TLX250-Tx as a monotherapy in advanced ccRCC17.
  • TLX101-Tx (iodofalan

    131

    I):

    • Enrolled first patient cohort in Part 1 (assessing safety and dose optimization) of IPAX BrIGHT, a pivotal trial of TLX101-Tx in patients with recurrent glioblastoma18.
    • Completed patient enrollment in IPAX-2, a Phase 1 study evaluating TLX101-Tx in patients with newly diagnosed glioblastoma19.

Telix Manufacturing Solutions (TMS): Expanding Telix’s global footprint to enable next phase of growth

Telix continues to invest in its global infrastructure, expanding its TMS operations. The TMS segment includes RLS Radiopharmacies (RLS), IsoTherapeutics (U.S.), and production (and R&D) facilities in Sacramento (U.S.), Seneffe (Belgium), North Melbourne (Australia) and Yokohama (Japan), representing a significantly expanded global production and manufacturing footprint. TMS is central to Telix’s long-term growth strategy and is expected to support increasing commercial demand and future pipeline expansion.

  • TMS reported US$146 million total segment revenue, which includes US$89 million from third-party product sales and service fees, and US$58 million internal revenue20, reflecting growth in sales of Illuccix and Gozellix through the RLS network and contributing to Group gross margin improvement.
  • TMS operating loss of US$33 million, includes US$10 million of depreciation and amortization on acquired intangibles.
  • Adjusted EBITDA loss for the TMS segment of US$23 million (H1 2025: Adjusted EBITDA loss of US$13 million), driven by increased investment in supply chain and logistics functions to meet anticipated therapeutics infrastructure needs.
  • Other TMS milestones in H1 2026 include:
    • Opened TMS North Melbourne, in partnership with the Melbourne Theranostic Innovation Centre (MTIC), aiming to accelerate the development of targeted radiopharmaceuticals.
    • TMS Seneffe completed first Good Manufacturing Practice (GMP) production run of a lutetium-based therapeutic candidate, validating the facility’s capabilities to support the manufacture of Telix’s next-generation therapeutics.

Guidance

  • FY 2026 revenue and other income expected to be in excess of US$1 billion, with revenue progressing in line with upper end of FY 2026 guidance of US$950 million to US$970 million and US$40 million of other income received from Regeneron.
  • Telix reaffirms R&D expenditure guidance of US$230 million to US$270 million, enabled by the Company’s strong commercial performance and initial payment of US$40 million received from Regeneron.

Corporate update

The Company advises that on August 20, 2026, it entered into an equity distribution agreement (EDA) with Morgan Stanley & Co. LLC and William Blair & Company, L.L.C. (together, the “Sales Agents”) to establish an “at-the-market” (ATM) facility. Under the ATM facility, the Company may, from time to time, determine to offer and issue new fully paid ordinary shares (“Shares”) at prevailing market prices in the form of American Depository Shares (ADSs). Each ADS represents one Share. The ATM facility will provide an opportunity to facilitate greater access to the Company’s securities on the Nasdaq stock exchange. The Company will control the offer process and has sole discretion over whether and when the ATM facility is used, the number of ADSs sold, and the minimum sale price of the ADSs. No offers or sales of ADSs will be made under the ATM facility unless and until a prospectus supplement has been filed with the U.S. Securities and Exchange Commission (SEC). The ATM facility will be subject to compliance with the ASX Listing Rules, including the Company’s available share placement capacity.  

Summary: Group financial results

  H1 2026 H1 2025
US$M US$M
Revenue 477   390  
Cost of sales (217 ) (181 )
Gross profit 260   209  
Other income 40   —  
Research and development (124 ) (82 )
Selling and marketing (58 ) (49 )
Manufacturing and distribution (29 ) (19 )
General and administration (49 ) (48 )
Other gains/(losses) (net) 6   (1 )
Operating profit 46   10  
Finance income 2   4  
Finance costs (19 ) (19 )
Profit/(loss) before income tax 29   (5 )
Income tax benefit 9   3  
Profit/(loss) after income tax 38   (2 )
Adjusted EBITDA

21
 		52   21  
Net cash from operating activities 23   18  



Investor call

An investor webcast and conference call will be held at 9:00 a.m. AEST today, Thursday, August 20, 2026 (7:00 p.m. EDT Wednesday, August 19, 2026). Participants can register for the webcast via this link:


https://s1.c-conf.com/diamondpass/10056417-pz2402.html

About Telix Pharmaceuticals Limited

Telix Pharmaceuticals (ASX: TLX, NASDAQ: TLX) is a commercial-stage global radiopharmaceutical company, advancing targeted theranostics to improve outcomes for people with cancer across the patient journey. Theranostics pairs a precision diagnostic with a targeted therapy to both diagnose and treat disease.

Telix’s commercial franchise is anchored by its prostate cancer imaging portfolio: Illuccix® (kit for the preparation of gallium-68 gozetotide injection), commercially available in 22 countries including the U.S. and Gozellix® (kit for the preparation of gallium-68 gozetotide injection), approved by the U.S. Food and Drug Administration (FDA). The Company’s late-stage therapeutic pipeline includes three investigational assets in pivotal-stage trials: TLX591-Tx (lutetium-177 (177Lu) rosopatamab tetraxetan) in prostate cancer, TLX101-Tx (131I-iodofalan) in recurrent glioblastoma, and TLX250-Tx (lutetium (177Lu) girentuximab tetraxetan) in kidney cancer, additionally complemented by a deep pipeline of next generation candidates.

Telix is headquartered in Melbourne, Australia, with operations across North America, Europe, Latin America and Asia-Pacific. For more information, visit www.telixpharma.com or follow Telix on LinkedIn, X and Facebook.

Investor Relations

Annie Kasparian        


[email protected]

Charlene Jaw


[email protected]

Guidance Disclaimer

The stated guidance is based on expected global and domestic economic conditions and is subject to known and unknown risks, uncertainties and other factors that may cause our actual results to differ materially. As such, investors are cautioned not to place undue reliance on this guidance and in particular Telix cannot guarantee a particular result. In compiling financial forecasts, a number of key variables that may have a significant impact on guidance have been identified and are listed below.

Key variables that could cause actual results to differ materially include: the success and timing of research and development activities; decisions by regulatory authorities regarding approval of our products as well as their decisions regarding label claims; competitive developments affecting our products; the ability to successfully market new and existing products; difficulties or delays in manufacturing; trade buying patterns and fluctuations in interest and currency exchange rates; legislation or regulations that affect product production, distribution, pricing, reimbursement, access or tax; acquisitions and divestitures; research collaborations; litigation or government investigations; and Telix’s ability to protect its patents and other intellectual property.

This announcement has been authorized for release by the Telix Pharmaceuticals Limited Board of Directors

No Offer or Solicitation

This announcement does not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of any securities of the Company in any jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offers or sales of ADSs will be made under the EDA unless and until a prospectus supplement has been filed with the SEC.

Telix has filed an automatic shelf registration statement on Form F-3ASR (File No. 333-293611) with the SEC, which became immediately effective upon filing. Any offering of securities in connection with the at-the-market offering will be made only by means of a prospectus supplement and the accompanying prospectus that form a part of the registration statement. A prospectus supplement describing the terms of the at-the-market offering will be filed with the SEC prior to any sales of ADSs under the EDA. When available, copies of the prospectus supplement and the accompanying base prospectus may be obtained from: Morgan Stanley & Co. LLC Attention: Prospectus Department 180 Varick Street, 2nd Floor New York, NY 10014 and William Blair & Company, L.L.C. Attention: Prospectus Department 150 North Riverside Plaza Chicago, IL 60606 or by accessing the SEC’s website at www.sec.gov. The at-the-market facility will be subject to the ASX Listing Rules framework for share issuances, including applicable placement and participation limits.

Legal Notices

You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website.

The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification.  To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement.

This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as “may”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “believe”, “outlook”, “forecast” and “guidance”, or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix’s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix’s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress, completion and results of Telix’s preclinical and clinical trials, and Telix’s research and development programs; Telix’s ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix’s product candidates, including TLX101-Px and TLX250-Px, manufacturing activities and product marketing activities; Telix’s sales, marketing and distribution and manufacturing capabilities and strategies; the commercialization of Telix’s product candidates, if or when they have been approved; Telix’s ability to obtain an adequate supply of raw materials at reasonable costs for its commercial products and product candidates; estimates of Telix’s expenses, future revenues and capital requirements; Telix’s financial performance; developments relating to Telix’s competitors and industry; the anticipated impact of U.S. and foreign tariffs and other macroeconomic conditions on Telix’s business, including as a result of war or other geopolitical conflicts; and the pricing and reimbursement of Telix’s product candidates, if and after they have been approved. Forward-looking statements may also include statements about the timing and use of the at-the-market facility established under the EDA, the potential sale of ADSs therefrom, Telix’s intentions regarding activation of the at-the-market facility, and the anticipated benefits of the at-the-market facility. Telix’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.

Non-IFRS Financial Measures. Telix’s results are reported under International Financial Reporting Standards (IFRS). This announcement includes various non-IFRS financial information to reflect its underlying performance, which have not been subject to audit or review. These non-IFRS measures include Adjusted EBITDA, which represents net earnings attributable to the Group excluding net finance costs, income tax expense, depreciation and amortization and other gains/(losses) (net). As required by SEC rules, we have provided reconciliations of these non-IFRS financial measures to the most directly comparable IFRS measures, which for Adjusted EBITDA, is Profit/(loss) before income tax. The Group believes that these non-IFRS measures, which are not considered to be a substitute for or superior to IFRS measures, provide stakeholders with additional useful information on the underlying trends, performance and position of the Group and are consistent with how business performance is measured internally. The non-IFRS measures are not defined by IFRS and therefore may not be directly comparable with other companies’ alternative performance measures.

Trademarks and Trade Names. All trademarks and trade names referenced in this press release are the property of Telix Pharmaceuticals Limited (Telix) or, where applicable, the property of their respective owners. For convenience, trademarks and trade names may appear without the ® or ™ symbols. Such omissions are not intended to indicate any waiver of rights by Telix or the respective owners. Trademark registration status may vary from country to country. Telix does not intend the use or display of any third-party trademarks or trade names to imply any affiliation with, endorsement by, or sponsorship from those third parties.

©2026 Telix Pharmaceuticals Limited. All rights reserved.

1 Group performance includes Telix Precision Medicine, Telix Therapeutics and Telix Manufacturing Solutions (TMS).
2 All comparisons to H1 2025 results.
3 Earnings before interest, tax, depreciation and amortization.
4 Telix ASX disclosure April 13, 2026.
5 Telix ASX disclosure April 14, 2026.
6 Telix media release July 17, 2026. Japan Registry of Clinical Trials identifier: JRCT2031250473.
7 Telix media release January 20, 2026.
8 Launch and brand names subject to final regulatory approval. Zircaix (TLX250-Px, ccRCC imaging), Pixclara and Pixlumi (TLX101-Px, glioma imaging).
9 Prescription Drug User Fee Act.
10 Telix ASX disclosure April 10, 2026.
11 Telix media release May 1, 2026.
12 Corrected CRL issued April 10, 2026.
13 Telix ASX disclosure March 10, 2026.
14 Telix ASX disclosure July 2, 2026.
15 Telix LinkedIn June 25, 2026. Australian New Zealand Clinical Trials Registry ID: ACTRN12625000971437.
16 Telix media release July 16, 2026. Australian New Zealand Clinical Trials Registry ID: ACTRN12626000034336.
17 Telix media release July 21, 2026. ClinicalTrials.gov ID: NCT07197580. Clear cell renal cell carcinoma.
18 ClinicalTrials.gov ID: NCT07100730.
19 ClinicalTrials.gov ID: NCT05450744.
20 Inter-segment revenue is eliminated on consolidation, refer to note 3 of the Interim financial report lodged today with the ASX.
21 Earnings before interest, tax, depreciation and amortization and other gains/(losses) (net).



Posted on

Statement of B&G Foods Regarding the Competition Bureau Challenge of Pending Sale of Green Giant Canada to Nortera

Statement of B&G Foods Regarding the Competition Bureau Challenge of Pending Sale of Green Giant Canada to Nortera

PARSIPPANY, N.J.–(BUSINESS WIRE)–
B&G Foods, Inc. (NYSE: BGS) today made the following statement regarding B&G Foods’ pending sale of Green Giant Canada to Nortera:

We are disappointed and disagree with the decision of the Competition Bureau (Canada) to ask the Competition Tribunal to block B&G Foods Canada’s proposed sale of the Green Giant and Le Sieur frozen and shelf-stable business in Canada to Nortera. While we acknowledge the Competition Bureau’s position, we believe the available evidence supports that this transaction is in the best interests of all interested stakeholders, including the Canadian consumer.

As part of this ongoing process, we remain in discussions with Nortera and we are evaluating multiple options, including potential legal, regulatory and operational alternatives. We are committed to pursuing alternatives that are in the best interests of all interested stakeholders, including our employees, stockholders, customers and Canadian consumers, while maintaining compliance with all applicable laws and regulations. We will provide further updates as developments arise.

About B&G Foods, Inc.

Based in Parsippany, New Jersey, B&G Foods and its subsidiaries manufacture, sell and distribute high-quality, branded shelf-stable and frozen foods across the United States, Canada and Puerto Rico. With B&G Foods’ diverse portfolio of more than 50 brands you know and love, including B&G, B&M, Bear Creek, College Inn,Cream of Wheat, Crisco, Dash,KitchenBasics, Las Palmas, Mama Mary’s, Maple Grove Farms, New York Style, Ortega, Polaner, Spice Islands and Victoria, there’s a little something for everyone. For more information about B&G Foods and its brands, please visit www.bgfoods.com.

Forward-Looking Statements

Statements in this press release that are not statements of historical or current fact constitute “forward-looking statements.” The forward-looking statements contained in this press release include, without limitation, statements related to B&G Foods’ pending divestiture of the Green Giant and Le Sieur frozen and shelf-stable business in Canada. Such forward-looking statements involve known and unknown risks, uncertainties and other unknown factors that could cause the actual results of B&G Foods to be materially different from the historical results or from any future results expressed or implied by such forward-looking statements. In addition to statements that explicitly describe such risks and uncertainties, readers are urged to consider statements labeled with the terms “believes,” “belief,” “expects,” “projects,” “intends,” “anticipates,” “assumes,” “could,” “should,” “estimates,” “potential,” “seek,” “predict,” “may,” “will” or “plans” and similar references to future periods to be uncertain and forward-looking. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in B&G Foods’ filings with the Securities and Exchange Commission, including under Item 1A, “Risk Factors” in B&G Foods’ most recent Annual Report on Form 10-K and in its subsequent reports on Forms 10-Q and 8-K. Investors are cautioned not to place undue reliance on any such forward-looking statements, which speak only as of the date they are made. B&G Foods undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

Investor Relations:

ICR, Inc.

Anna Kate Heller

[email protected]

Media Relations:

ICR, Inc.

Matt Lindberg

[email protected]

KEYWORDS: New Jersey United States North America Canada

INDUSTRY KEYWORDS: Retail Professional Services Food/Beverage Finance

MEDIA:

Logo
Logo
Posted on

Hyve Solutions Expands Manufacturing Footprint With Reno and North Las Vegas Campuses

Hyve Solutions Expands Manufacturing Footprint With Reno and North Las Vegas Campuses

New Campuses Grow Hyve’s U.S. Advanced Manufacturing Footprint to Meet Rising DigitaI Infrastructure Demand

FREMONT, Calif.–(BUSINESS WIRE)–Hyve Solutions Corporation, a US-based design and manufacturing partner for compute, storage, and networking systems in AI, cloud, and digital infrastructure, and a wholly owned subsidiary of TD SYNNEX Corporation (NYSE: SNX), today announced two new advanced manufacturing campuses in Nevada, one in Reno and one in North Las Vegas, to support increased customer demand.

The Reno campus will serve as Hyve’s flagship site in the state, occupying approximately 624,000 square feet of advanced manufacturing space and expands the company’s current domestic SMT (surface-mount technology) capacity. This site is paired with an additional Hyve facility in North Las Vegas, extending the company’s footprint into Southern Nevada. Together, the two campuses are expected to create approximately 3,000 new jobs.

“Nevada gives us the space, the workforce and the business climate to grow our manufacturing capability at the scale our customers need,” said Jerry Kagele, President of Hyve Solutions. “Expanding our advanced manufacturing capacity lets us add this work here in the United States, and we’re proud to be creating good, long-term careers as we do it.”

Economic Impact and Workforce Growth

Open roles will span production, engineering, quality, supply chain, warehouse and operations positions, offering both hourly and salaried opportunities across permanent, trade and contingent roles. Compensation includes wages above Nevada’s statewide average, along with medical, vision and dental benefits, and room to grow into new roles as the campuses scale.

Hyve is actively recruiting for these positions and is ramping hiring as quickly as possible, drawing on Nevada’s workforce and university talent to fill key roles across both campuses. Open roles can be found on HyveSolutions.com.

Hyve worked with the Economic Development Authority of Western Nevada (EDAWN), the Las Vegas Global Economic Alliance (LVGEA) and the Governor’s Office of Economic Development (GOED) throughout the site selection process, with the company’s applications approved by the GOED Board. The investment reflects Nevada as a growing hub for advanced manufacturing.

About Hyve Solutions Corporation

Hyve Solutions transforms complex engineering challenges into production reality for technology innovators building AI, cloud, and connected infrastructure. As a US-based design and manufacturing partner, the company rapidly delivers fast, agile execution through deep technical partnerships and co-innovation, and supply chain clarity. Hyve’s integrated ODM, CM, and SI capabilities eliminate vendor complexity while accelerating time-to-market with single-partner accountability from design through scale. The company co-innovates with deep engineering expertise, treating customer success as its own while building tomorrow’s digital infrastructure.

Hyve Solutions is a wholly owned subsidiary of TD SYNNEX Corporation (NYSE: SNX). For more information, visit hyvesolutions.com, email [email protected], or call (855) 869-6973.

About TD SYNNEX Corporation

TD SYNNEX (NYSE: SNX) is a leading global distributor and solutions aggregator for the IT ecosystem. We’re an innovative partner helping more than 150,000 customers in 100+ countries to maximize the value of technology investments, demonstrate business outcomes, and unlock growth opportunities. Headquartered in Clearwater, Florida, and Fremont, California, TD SYNNEX’s 23,000 co-workers are dedicated to uniting compelling IT products, services and solutions from 2,500+ best-in-class technology vendors. Our edge-to-cloud portfolio is anchored in some of the highest-growth technology segments including cloud, cybersecurity, big data/analytics, AI, IoT, mobility and everything as a service. TD SYNNEX is committed to serving customers and communities, and we believe we can have a positive impact on our people and our planet, intentionally acting as a respected corporate citizen. We aspire to be a diverse and inclusive employer of choice for talent across the IT ecosystem. For more information, visit www.TDSYNNEX.com, follow our newsroom or find us on LinkedIn, Facebook and Instagram.

Media Contact:

Bill Fox

Hughes Agency

For Hyve Solutions/ TD SYNNEX Corporation

(864) 271-0718

[email protected]

KEYWORDS: California Nevada United States North America

INDUSTRY KEYWORDS: Other Manufacturing Technology Engineering Other Technology Software Manufacturing Networks Hardware Data Management Artificial Intelligence

MEDIA:

Logo
Logo
Posted on

Mechanics Bancorp Declares Third Quarter 2026 Cash Dividend

Mechanics Bancorp Declares Third Quarter 2026 Cash Dividend

WALNUT CREEK, Calif.–(BUSINESS WIRE)–
Mechanics Bancorp (Nasdaq: MCHB) today announced it has declared a cash dividend of $0.25 per share of Class A common stock and $2.50 per share of Class B common stock, each payable on September 1, 2026, to shareholders of record as of the close of business on August 29, 2026.

About Mechanics Bancorp

Mechanics Bancorp is headquartered in Walnut Creek, Calif., and is the financial holding company of Mechanics Bank, a full-service, FDIC-insured bank with $21.2 billion in assets as of June 30, 2026, and 166 branches across California, Oregon, Washington and Hawaii. Founded in 1905 to help families, businesses and communities prosper, Mechanics Bank offers a wide range of products and services in consumer and business banking, commercial lending, cash management services, private banking, and comprehensive wealth management and trust services.

To learn more, visit www.MechanicsBank.com.

Nathan Duda

Executive Vice President, Chief Financial Officer

[email protected]

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Banking Asset Management Professional Services Finance

MEDIA:

Posted on

Virtuix Reports First Quarter Fiscal Year 2027 Results as Omni One Orders Increase 150% Following Meta Launch

 Orders Increased 72% Year-over-Year and Approximately 150% Since the Launch of Omni One for Quest as Meta Launch Drives Accelerating Consumer Demand

Gross Profit Increased 29%; Gross Margin Expanded to 30% from 17%

Defense Expansion Accelerates with Counter-UAS Trainer and Infantry Fireteam Trainer for U.S. Marine Corps, SBIR Phase I Award from U.S. Air Force, and First Deployment to Air National Guard

Omni One Enterprise Expands to Tesla for Humanoid Robot Teleoperation, NASA for Moon and Mars Exploration Analog Mission, and Sirica Therapeutics for AI-Driven Healthcare

Management to Host Conference Call Tomorrow at 8:30 a.m. Eastern Time

AUSTIN, Texas, Aug. 19, 2026 (GLOBE NEWSWIRE) — Virtuix Holdings Inc. (NASDAQ: VTIX) (the “Company”), a leading developer of AI-driven, full-body simulation systems, today reported financial and operational results for the first quarter of fiscal year 2027 ended June 30, 2026.

Key First Quarter Fiscal 2027 Results and Subsequent Highlights

  • New orders for Omni One systems in the quarter increased 72% year-over-year and approximately 150% since the launch of Omni One for Quest compared to the same period last year, with similar momentum continuing into the current quarter.
  • Net sales were $0.8 million compared to $1.0 million in the prior-year period, which benefited from fulfilment of the final batch of legacy backlog accumulated since 2023. Current-quarter revenue was generated from newly acquired customers.
  • Gross profit increased 29% and gross margin expanded to 30% from 17% in the prior-year period, reflecting higher Omni One system pricing.
  • Net loss per share narrowed from ($0.28) to ($0.22) per share.
  • Advanced its U.S. Marine Corps Infantry Fireteam Trainer as lead systems integrator with the selection of AVRT to provide weapons tracking and immersive training content. Delivery of the pilot system to the U.S. Marine Corps in Quantico, VA, is expected in the fourth calendar quarter of 2026.
  • Entered the counter-drone training market through integration with LeadTech’s Counter-UAS Personnel Trainer for evaluation by the U.S. Marine Corps.
  • Awarded U.S. Air Force funding under Phase I of the AFWERX SBIR program to advance development of its Virtual Terrain Walk (“VTW”) platform for military mission planning and leader rehearsals.
  • Delivered an Omni One system to the Pennsylvania Air National Guard for use of AI-driven virtual reality military training, marking the Company’s first deployment with the Air National Guard.
  • Sold its first Omni One Enterprise system to Tesla, Inc. for the company’s Optimus humanoid robot division, where the system is being used for teleoperation, enabling an operator to remotely control a humanoid robot in real time.
  • Won the Company’s second consecutive 2026 Auggie Award for Best Interaction Product at Augmented World Expo, recognizing Omni One as part of a humanoid robot teleoperation system developed with the University of Central Florida’s Institute for Simulation & Training.
  • Selected for NASA’s Moon and Mars Exploration Analog (MMEA) mission, with Omni One supporting simulated extravehicular activities during a year-long study beginning in 2027.
  • Partnered with Sirica Therapeutics to advance AI-driven autism therapy, delivering two Omni One systems to its treatment center. Sirica plans to establish approximately 100 treatment centers nationwide.

Management Commentary

“The first quarter of fiscal 2027 was one of the strongest commercial quarters in our Company’s recent history,” said Jan Goetgeluk, CEO of Virtuix. “New orders for Omni One systems increased 72% year-over-year, and have increased approximately 150% since the launch of Omni One for Quest in collaboration with Meta, a trend we have seen continue into the current quarter.

“While reported revenue was lower year-over-year, that comparison reflects the completion of our legacy preorder backlog: revenue in the prior-year period was driven largely by the fulfillment of the final batch of the large backlog of Omni One orders accumulated since the start of our preorder period in August 2023, whereas revenues this quarter resulted from sales to newly acquired customers. We believe new orders are the better forward indicator of the accelerating demand we are currently seeing.

“Our unit economics also continued to improve. Gross profit increased 29% year-over-year and gross margin expanded to 30% from 17%, primarily reflecting the higher selling price of the complete Omni One system in the first quarter of fiscal 2027 compared to the price of units delivered in the prior-year period. We ended the quarter with $7.4 million of cash.

“The launch of the Made for Meta certified Omni One for Quest has expanded our addressable market to millions of active Quest users and is already reshaping our order profile. We believe it represents an important step toward our goal of driving continued consumer sales growth and bringing our immersive, physically engaging entertainment experience to millions of households nationwide. We believe we are only scratching the surface of the potential of our Meta partnership, as we are exploring joint marketing opportunities and the bundling of Virtuix and Meta products.

“Our defense business continues to gain momentum. As lead systems integrator, we’re advancing the development of the U.S. Marine Corps Infantry Fireteam Trainer, while also expanding into the counter-drone training market through LeadTech’s C-UAS Personnel Trainer, and we completed our first deployment with the Air National Guard.

“We are also pursuing inorganic growth in the defense sector. Our special committee is actively reviewing acquisition opportunities in the defense training and simulation industry, with a focus on companies with annual revenues in the $10 million to $50 million range that would provide immediate access to government contract vehicles and recurring defense revenues.

“Beyond defense, we expanded into enterprise robotics through our first sale to Tesla’s Optimus program, were selected for NASA’s moon and mars mission, and earned our second consecutive Auggie Award, demonstrating the expanding commercial potential of Omni One.”

“In healthcare, we signed a strategic partnership with Sirica Therapeutics and shipped two Omni One systems to Sirica’s San Francisco Bay Area treatment center to advance AI-driven autism therapy. Sirica announced plans to establish approximately 100 treatment centers nationwide, and we believe full-body movement within AI-enabled environments may play an increasingly important role across next-generation healthcare and therapeutic applications.

“Looking ahead, we are focused on converting the order momentum we are seeing in our consumer business into accelerating revenue growth, advancing our defense programs toward larger awards, completing one or more acquisitions in the defense space, and expanding into enterprise robotics and healthcare applications. Through our multi-use platform strategy, we intend to complement high-volume consumer sales with high-value defense and enterprise contracts, including recurring revenues from software licensing and customized simulation development. We look forward to additional updates in the coming months as we seek to bring long-term value to our stockholders,” concluded Goetgeluk.

First Quarter Financial Results

Net sales for the three months ended June 30, 2026 were $0.8 million, a 26% decrease compared to $1.0 million for the prior year period. The overall higher revenue in the three months ended June 30, 2025 was primarily attributable to the fulfillment of the final batch of the large backlog of Omni One orders accumulated since the start of the preorder period in August 2023, whereas revenues in the first quarter of fiscal 2027 resulted from sales to newly acquired customers. New orders for Omni One systems increased 72% in the three months ended June 30, 2026 compared to the same period last year.

Gross profit in the three months ended June 30, 2026 increased 29% to $227,158, compared to $176,077 in the prior year period. Gross margin as a percentage of revenues expanded to 30% in the three months ended June 30, 2026, from 17% in the prior year period. The improvement was primarily the result of the higher selling price of the complete Omni One system in the first quarter of fiscal 2027 compared to the price of units delivered in the prior-year period.

Total operating expenses increased by $1.9 million, or 86%, to $4.1 million in the three months ended June 30, 2026, compared to $2.2 million in the prior year period. The increase was primarily due to a non-cash $0.7 million increase in stock compensation expense and a $1.2 million increase in professional services fees related to operating as a publicly traded company, including legal, accounting, investor relations, and other professional services.

Total other expense was $3.2 million in the three months ended June 30, 2026, compared to $0.2 million in the prior year period. The increase was primarily attributable to non-cash expenses, including $2.5 million of interest expense and non-cash amortization of debt discount related to the Company’s convertible notes.

Net loss for the three months ended June 30, 2026 was ($7.2) million compared to ($2.3) million for the three months ended June 30, 2025. The increase in net loss primarily reflects $4.0 million of non-cash charges and higher operating expenses, partially offset by the improvement in gross profit.

Adjusted EBITDA loss for the three months ended June 30, 2026 was ($3.1) million, compared to a loss of ($1.9) million for the three months ended June 30, 2025.

Net loss per basic and diluted share for the three months ended June 30, 2026 was ($0.22), compared to ($0.28) for the prior year period.

Cash and cash equivalents totaled $7.4 million as of June 30, 2026, compared to $9.5 million as of March 31, 2026.

First Quarter Fiscal Year 2027 Financial Results Conference Call

Virtuix Founder, Chief Executive Officer, and Chairman Jan Goetgeluk and Chief Financial Officer Thomas McGinnis will host the conference call, followed by a question-and-answer period. The conference call will be accompanied by a presentation, which can be viewed during the webcast or accessed following the call via the investor relations section of the Company’s website here.

To access the call, please use the following information:

Date: Thursday, August 20, 2026
Time: 8:30 a.m. Eastern time
U.S. dial-in: 1-877-425-9470
International dial-in: 1-201-389-0878
Conference ID: 13761831
Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1770243&tp_key=19ebd0fc8f

A telephone replay will be available approximately three hours after the call and will run through Thursday, September 3. To listen, please dial 1-844-512-2921 (U.S.) or 1-412-317-6671 (international) and use replay PIN 13761831. A webcast replay will also be available on the Company’s investor relations website.

Note About Non-GAAP Financial Measures

Adjusted EBITDA is a non-GAAP financial measure. The Company defines Adjusted EBITDA as net loss adjusted to exclude: (i) provision for (benefit from) income taxes, (ii) interest expense, net, (iii) depreciation and amortization, (iv) stock-based compensation expense, (v) financing expense, (vi) loss on extinguishment of debt, and (vii) gains or losses from changes in the fair value of financial instruments. Adjusted EBITDA is not calculated in accordance with U.S. generally accepted accounting principles (“GAAP”) and should not be considered in isolation or as a substitute for net loss or any other measure of performance calculated in accordance with GAAP. The Company believes Adjusted EBITDA provides useful supplemental information to investors regarding the performance of its ongoing operations, and management uses it to evaluate operating performance and allocate resources. Because Adjusted EBITDA is not determined in accordance with GAAP and is susceptible to varying calculations, it may not be comparable to similarly titled measures presented by other companies. A reconciliation of net loss, the most directly comparable GAAP measure, to Adjusted EBITDA is presented below.

    For the Three Months Ended

June 30, 		 
    2026     2025  
    (Unaudited)  
Reconciliation of GAAP net loss to Adjusted EBITDA      
NET LOSS   $ (7,170,566 )   $ (2,307,155 )
Plus:                
Taxes     49,391       23,418  
Interest expense, net(1)     2,539,429       119,114  
Depreciation and amortization     142,953       158,776  
EBITDA   $ (4,438,793 )   $ (2,005,847 )
Plus:                
Stock-based compensation(2)     722,937       10,897  
Financing expense(3)     584,150       0  
Loss on extinguishment of debt     431,224       122,864  
Less:                
Change in fair value of financial instruments     (372,350 )     0  
ADJUSTED EBITDA   $ (3,072,832 )   $ (1,872,086 )
 

(1) Interest expense for the three months ended June 30, 2026 includes $2,052,255 of non-cash amortization of debt discount related to the Company’s financing arrangements. The debt discount results from the issuance of warrants, original issue discounts, related closing costs, and embedded derivative bifurcation, which are being amortized to interest expense over the term of the notes.
(2) Stock-based compensation expense for the three months ended June 30, 2026 consisted of non-cash expenses of $103,080 related to equity awards granted to vendors and service providers and $619,857 related to equity awards granted to employees, officers, and directors. Stock-based compensation expense for the three months ended June 30, 2025 consisted entirely of employee, officer, and director awards.
(3) Financing expense represents a non-cash charge recognized in connection with amendments to certain outstanding warrants during the three months ended June 30, 2026.

About Virtuix

Virtuix Holdings Inc. (NASDAQ: VTIX) is a leading manufacturer of AI-driven, full-body simulation systems for consumer, enterprise, healthcare, and defense markets. The company’s premier portfolio of “Omni” omni-directional treadmills enables players to walk and run in 360 degrees without boundaries inside AI-generated worlds. With a focus on immersive entertainment, defense training, and enterprise applications, Virtuix continues to push the boundaries of full-body XR and AI-driven immersive experiences for users worldwide. For more information, visit virtuix.com.

Please visit the Company’s new Investor Relations website at invest.virtuix.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include, but are not limited to, statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as “may,” “will,” “intend,” “should,” “believe,” “expect,” “would,” “potential,” “continue,” “focused,” “looking ahead,” “plans to,” “seek to,” or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements in this press release include, without limitation, statements regarding: the Company’s expectation that recent new order growth will continue and will convert into future revenue growth, including statements about accelerating consumer demand and similar momentum continuing into the current quarter; the Company’s plans to pursue strategic acquisitions in the defense training and simulation industry, including its focus on companies with annual revenues in the $10 million to $50 million range and the potential benefits, synergies, and impact on revenues or shareholder value of any such acquisition; the Company’s position in the defense training market and plans to advance its defense programs toward larger awards; the anticipated timing and scope of the U.S. Marine Corps Infantry Fireteam Trainer program, including expected delivery of the pilot system to Quantico, VA in the fourth calendar quarter of 2026; the outcome of counter-drone and other military evaluations, including the LeadTech Counter-UAS Personnel Trainer for evaluation by the U.S. Marine Corps; expectations regarding government contract opportunities, including AFWERX SBIR Phase I funding and potential Phase II and Phase III funding; expectations regarding the Meta collaboration and the Omni One for Quest launch, including potential joint marketing opportunities and bundling of Virtuix and Meta products, and the Company’s goal of driving continued consumer sales growth and bringing its experience to millions of households nationwide; expectations regarding enterprise and robotics applications, including the Company’s relationship with Tesla’s Optimus humanoid robot program; expectations regarding the NASA Moon and Mars Exploration Analog mission, including simulated extravehicular activities during a year-long study beginning in 2027; expectations regarding therapeutic and healthcare applications, including the Sirica Therapeutics partnership and Sirica’s plans to establish approximately 100 treatment centers nationwide; statements regarding future gross margin improvement and unit economics; statements regarding the Company’s multi-use platform strategy, including complementing high-volume consumer sales with high-value defense and enterprise contracts and recurring revenues from software licensing and customized simulation development; and statements regarding future market growth, demand, and bringing long-term value to stockholders. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company’s expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to: the Company’s ability to convert new orders into revenue; the Company’s need for additional capital and its ability to obtain financing on acceptable terms or at all; the Company’s limited cash runway and the substantial doubt regarding the Company’s ability to continue as a going concern, as disclosed in the Company’s latest Quarterly Report on Form 10-Q; the Company’s ability to meet its convertible note and other debt obligations when due; risks related to the Company’s outstanding indebtedness; the Company’s ability to identify, negotiate, and complete acquisitions on favorable terms or at all; the ability to successfully integrate any acquired business; the ability to achieve anticipated synergies, revenues, or shareholder value from any acquisition; risks related to government contracting, including contract cancellations, modifications, or funding changes; uncertainties regarding the timing and success of defense program milestones, evaluations, and deployments; the uncertainties related to market conditions, including consumer demand for virtual reality products; the Company’s ability to maintain its collaboration with Meta and achieve anticipated benefits therefrom; risks related to partnerships and collaborations with third parties, including Tesla, NASA, Sirica Therapeutics, and other enterprise customers; risks related to international expansion; competition in the virtual reality, defense training, and simulation markets; and other factors discussed in the “Risk Factors” section of the Company’s filings with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company’s filings with the SEC, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof, except as required by law.

Visit Us on Social Media:

LinkedIn



Instagram



Facebook



YouTube



TikTok



X

Company Contact

Lauren Premo
Virtuix Holdings Inc.
[email protected]

Investor Relations Contact

Chris Tyson
MZ Group
Direct: 949-491-8235
[email protected]

VIRTUIX HOLDINGS INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
JUNE 30, 2026 (UNAUDITED) AND MARCH 31, 2026
 
ASSETS
 
          March 31,  
    June 30,

2026 		    2026

(As Revised) 		 
CURRENT ASSETS            
Cash and cash equivalents   $ 7,443,869     $ 9,471,288  
Receivables, net of allowance for credit losses     465,403       379,289  
Inventory     1,373,385       1,188,623  
Prepaids and other current assets     764,516       897,109  
TOTAL CURRENT ASSETS     10,047,173       11,936,309  
                 
NONCURRENT ASSETS                
Property and equipment     1,414,460       1,413,294  
Less: accumulated depreciation     (1,066,258 )     (1,034,984 )
Net property and equipment     348,202       378,310  
                 
Intangibles     2,802,690       2,797,741  
Less: accumulated amortization     (1,370,066 )     (1,258,387 )
Net intangibles     1,432,624       1,539,354  
                 
Investment in joint venture     –       40,619  
                 
Other assets     50,975       87,264  
                 
Right-of-use asset – operating     701,512       779,514  
TOTAL NONCURRENT ASSETS     2,533,313       2,825,061  
                 
TOTAL ASSETS   $ 12,580,486     $ 14,761,370  
 

LIABILITIES AND STOCKHOLDERS’ (DEFICIT) EQUITY
 
          March 31,  
    June 30,

2026 		    2026

(As Revised) 		 
CURRENT LIABILITIES            
Accounts payable   $ 662,290     $ 721,792  
Accrued expenses     588,772       559,517  
Deferred revenue     639,551       666,327  
Gift card liability     445,744       446,252  
Current portion of notes payable, net of discount and unamortized deferred loan costs     9,658,998       5,328,477  
Derivative liabilities at fair value     1,900,649       2,709,817  
Current portion of EIDL loan     576       570  
Lease liability – operating     256,966       286,702  
TOTAL CURRENT LIABILITIES     14,153,546       10,719,454  
                 
LONG-TERM LIABILITIES                
Notes payable, net of discount and unamortized deferred loan costs     1,039,518       2,428,835  
EIDL loan     23,371       23,517  
Lease liability, net of current portion – operating     444,546       492,812  
TOTAL LONG-TERM LIABILITIES     1,507,435       2,945,164  
                 
TOTAL LIABILITIES     15,660,981       13,664,618  
                 
STOCKHOLDERS’ (DEFICIT) EQUITY                
                 
Class A common stock, $.001 par value, 300,000,000 shares authorized at June 30, 2026 and March 31, 2026 and 28,898,026 and 28,562,693 shares issued and outstanding at June 30, 2026 and March 31, 2026, respectively     28,897       28,562  
Class B common stock, $.001 par value, 50,000,000 shares authorized at June 30, 2026 and March 31, 2026 and 4,000,000 shares issued and outstanding at June 30, 2026 and March 31, 2026     4,000       4,000  
Additional paid-in capital     83,403,609       80,410,625  
Accumulated deficit     (86,517,001 )     (79,346,435 )
TOTAL STOCKHOLDERS’ (DEFICIT) EQUITY     (3,080,495 )     1,096,752  
                 
TOTAL LIABILITIES AND STOCKHOLDERS’ (DEFICIT) EQUITY   $ 12,580,486     $ 14,761,370  
 

VIRTUIX HOLDINGS INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
FOR THE THREE MONTHS ENDED JUNE 30, 2026 AND 2025 (UNAUDITED)
 
    Three Months Ended

June 30, 		 
    2026     2025  
             
SALES   $ 767,300       1,032,136  
                 
COST OF GOODS SOLD     540,142       856,059  
                 
GROSS PROFIT     227,158       176,077  
                 
OPERATING EXPENSES                
Selling expenses     738,978       1,049,658  
General and administrative expenses     3,080,778       959,392  
Research and development expenses     309,375       208,716  
                 
TOTAL OPERATING EXPENSES     4,129,131       2,217,766  
                 
LOSS FROM OPERATIONS     (3,901,973 )     (2,041,689 )
                 
OTHER INCOME (EXPENSE)                
Loss on disposal of assets     (5,132 )     –  
Interest income     163       185  
Other income     9,002       –  
Loss on extinguishment of debt     (431,224 )     (122,864 )
Loss on derecognition of equity method investment     (40,619 )     –  
Change in fair value of derivative liabilities     349,128       –  
Change in fair value of debt     23,222       –  
Interest expense     (2,539,592 )     (119,299 )
Financing expense     (584,150 )     –  
                 
TOTAL OTHER EXPENSE, NET     (3,219,202 )     (241,978 )
                 
PROVISION FOR INCOME TAX     49,391       23,418  
                 
                 
                 
                 
SHARE OF LOSS IN JOINT VENTURE     –       (70 )
                 
NET LOSS   $ (7,170,566 )   $ (2,307,155 )
                 
Weighted average common shares outstanding:                
Basic and Diluted     32,787,960       8,259,732  
Net loss per share:                
Basic and Diluted   $ (0.22 )   $ (0.28 )
 

VIRTUIX HOLDINGS INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

FOR THE THREE MONTHS ENDED JUNE 30, 2026 AND 2025 (UNAUDITED)
 
    Three Months Ended

June 30, 		 
    2026     2025  
CASH FLOWS FROM OPERATING ACTIVITIES            
Net loss   $ (7,170,566 )   $ (2,307,155 )
Adjustments to reconcile net loss to net cash used in operating activities:                
Depreciation and amortization expense     142,953       158,776  
Amortization of discount on notes payable     2,052,255       973  
Amortization of loan costs     270,970       1,125  
Credit loss expense     6,094       36,918  
Lease expense – right of use operating     78,002       68,170  
Stock-based compensation     619,857       10,897  
Change in fair value of derivative liabilities     (349,128 )     –  
Change in fair value of debt     (23,222 )     –  
Loss on disposal of assets     5,132       –  
Loss on derecognition of the equity method investment     40,619       –  
Share of loss in joint venture     –       70  
Warrant modification expense     584,150       –  
Loss on extinguishment of debt     431,224       122,864  
Stock issuance in exchange for services     103,080       –  
Payments on operating leases     (91,244 )     (82,591 )
Due from related parties     –       21,345  
(Increase) decrease in assets:                
Prepaid expenses and other current assets     132,593       17,993  
Accounts receivable     (92,208 )     (53,222 )
Other assets     36,289       810  
Inventory     (184,762 )     292,557  
Increase (decrease) in liabilities:                
Accounts payable     (59,502 )     351,188  
Accrued expenses     186,627       193,645  
Gift card liability     (508 )     –  
Operating lease liabilities     13,242       14,421  
Deferred revenue     (26,776 )     (339,906 )
CASH USED IN OPERATING ACTIVITIES     (3,294,829 )     (1,491,122 )
                 
CASH FLOWS FROM INVESTING ACTIVITIES                
Cash paid for purchases of property and equipment     (6,298 )     (1,304 )
Cash paid for purchases of intangibles     (4,949 )     (2,192 )
CASH USED IN INVESTING ACTIVITIES     (11,247 )     (3,496 )
                 
CASH FLOWS FROM FINANCING ACTIVITIES                
Issuance of preferred stock     –       1,493,873  
Payments on short-term notes payable     (4,603 )     (110,992 )
Payments on long-term notes payable     (140 )     (134 )
Proceeds from short-term notes payable     –       217,678  
Warrants exercised     1,380,000       79  
Equity issuance costs     (96,600 )     –  
CASH PROVIDED BY FINANCING ACTIVITIES     1,278,657       1,600,504  
                 
NET (DECREASE) INCREASE IN CASH     (2,027,419 )     105,886  
                 
CASH AT BEGINNING OF PERIOD     9,471,288       477,908  
                 
CASH AT END OF PERIOD   $ 7,443,869     $ 583,794  



Posted on

Ocean Power Technologies Provides Update to Previously Announced Preliminary Fiscal 2026 Financial Results

MONROE TOWNSHIP, N.J., Aug. 19, 2026 (GLOBE NEWSWIRE) — Ocean Power Technologies, Inc. (“OPT” or the “Company”) (NYSE American: OPTT), a leader in maritime operational infrastructure, autonomous ocean systems, and AI-enabled maritime intelligence solutions, today provided an update to the preliminary financial results previously announced on July 23, 2026.

Following completion of additional audit procedures and consultation with the National Office of the Company’s independent registered public accounting firm, the Company revised its accounting treatment with respect to certain revenue, costs and other accounting matters identified in connection with the completion of the audit. As a result, certain previously reported preliminary financial results have been updated.

The revisions for the fiscal year ended April 30, 2026 decrease revenue by approximately $0.4 million from $4.1 million to $3.7 million, decreased gross loss by approximately $2.2 million, from the previously reported gross loss of $8.1 million to $5.9 million, and decreased operating loss by approximately $1.5 million for the same period. The revisions also increased net loss by approximately $5.2 million, from approximately $43.7 million to $48.9 million. Net loss for the fiscal year ended April 30, 2025 also increased by approximately $3.0 million due to the recognition of a loss on changes in fair value of a financial instrument.

Importantly:

  • The revisions result from changes in accounting treatment and do not reflect changes in the Company’s underlying business activities.
  • The revisions have no impact on the Company’s cash or cash flows.
  • The revisions do not change the terms of the Company’s customer contracts or the Company’s contractual rights and obligations.

About Ocean Power Technologies
OPT provides intelligent maritime solutions and services that enable safer, cleaner, and more productive ocean operations for the defense and security, oil and gas, science and research, and offshore wind markets, including Merrows™, which provides AI capable seamless integration of Maritime Domain Awareness Systems across platforms. Our PowerBuoy® platforms provide clean and reliable electric power and real-time data communications for remote maritime and subsea applications. We also provide WAM-V® autonomous surface vessels (ASVs) and marine robotics services. The Company’s headquarters is located in Monroe Township, New Jersey and has an additional office in Richmond, California. To learn more, visit www.OceanPowerTechnologies.com.

Forward-Looking Statements

This release may contain forward-looking statements that are within the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are identified by certain words or phrases such as “may”, “will”, “aim”, “will likely result”, “believe”, “expect”, “will continue”, “anticipate”, “estimate”, “intend”, “plan”, “contemplate”, “seek to”, “future”, “objective”, “goal”, “project”, “should”, “will pursue” and similar expressions or variations of such expressions. These forward-looking statements reflect the Company’s current expectations about its future plans and performance. These forward-looking statements rely on a number of assumptions and estimates that could be inaccurate and subject to risks and uncertainties. Actual results could vary materially from those anticipated or expressed in any forward-looking statement made by the Company. Please refer to the Company’s most recent Forms 10-Q and 10-K and subsequent filings with the U.S. Securities and Exchange Commission for further discussion of these risks and uncertainties. Except as may be required by applicable law, the Company undertakes no, and expressly disclaims any, obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, circumstances or otherwise after the date of this press release, and you are cautioned not to rely upon them unduly.

Financial Tables Follow

Additional information may be found in the Company’s Annual Report on Form 10-K that will be filed with the U.S. Securities and Exchange Commission. The Form 10-K is accessible at www.sec.gov or the Investor Relations section of the Company’s website (https://investors.oceanpowertechnologies.com/).

Contact Information

Investors: 609-730-0400 x401 or [email protected]
Media: 609-730-0400 x402 or [email protected]

 Ocean Power Technologies, Inc. and Subsidiaries
Consolidated Balance Sheets
(in thousands, except share data)
             
    April 30, 2026     April 30, 2025  
ASSETS                
Current assets:                
Cash and cash equivalents   $ 8,719     $ 6,715  
Restricted cash, short-term     154       —  
Accounts receivable, net     587       1,191  
Contract assets     590       1,088  
Inventory     3,190       4,222  
Other current assets     2,648       400  
Total current assets   $ 15,888     $ 13,616  
Property and equipment, net     10,255       3,444  
Intangibles, net     3,357       3,490  
Right-of-use assets, net     1,886       1,552  
Restricted cash, long-term     —       154  
Goodwill     8,537       8,537  
Total assets   $ 39,923     $ 30,793  
LIABILITIES AND SHAREHOLDERS’ EQUITY                
Current liabilities:                
Accounts payable   $ 4,366     $ 568  
Earn out payable     150       300  
Convertible notes payable (Note 13)     10,428       —  
Accrued expenses     4,232       1,271  
Contract liabilities, current     6,029       —  
Right-of-use liabilities, current portion     1,202       1,150  
Total current liabilities   $ 26,407     $ 3,289  
Deferred tax liability     203       203  
Right-of-use liabilities, less current portion     837       649  
Total liabilities   $ 27,447     $ 4,141  
Commitments and contingencies (Note 15)                
Shareholders’ Equity:                
Preferred stock, $0.001 par value; authorized 5,000,000 shares, none issued or outstanding   $ —     $ —  
Common stock, $0.001 par value; authorized 400,000,000 and 300,000,000 shares, respectively, issued 231,145,998 and 172,050,563 shares, respectively, and outstanding 228,460,085 and 171,263,086 shares, respectively     231       172  
Treasury stock, at cost; 2,685,913 and 787,477 shares, respectively     (1,825 )     (1,018 )
Additional paid-in capital     395,031       359,544  
Accumulated deficit     (380,961 )     (332,046 )
Accumulated other comprehensive loss     —       —  
Total shareholders’ equity     12,476       26,652  
Total liabilities and shareholders’ equity   $ 39,923     $ 30,793  

Ocean Power Technologies, Inc. and Subsidiaries

Consolidated Statements of Operations

(in thousands, except per share data)
             
    Fiscal year ended April 30,  
    2026     2025  
Product & service revenue   $ 3,098     $ 5,408  
Lease revenue     639       453  
Total revenue     3,737       5,861  
Cost of revenue     9,658       4,201  
Gross margin     (5,921 )     1,660  
Operating expenses     32,442       23,346  
Operating loss   $ (38,363 )   $ (21,686 )
Interest (expense)/income, net     (2,785 )     47  
Other expense     (878 )     (23 )
Change in fair value of financial instrument     (5,690 )     (2,956 )
Loss on extinguishment of debt     (1,186 )     (838 )
Foreign exchange loss     (13 )     (45 )
Loss before income taxes   $ (48,915 )   $ (25,500 )
Income tax benefit     —       1,034  
Net loss   $ (48,915 )   $ (24,466 )
Basic and diluted net loss per share   $ (0.25 )   $ (0.19 )
Weighted average shares used to compute basic and diluted net loss per share     194,349,416       126,913,998  

OCEAN POWER TECHNOLOGIES, INC. AND SUBSIDIARIES

Consolidated Statements of Cash Flows

(in thousands)
       
    Fiscal year ended April 30,  
    2026     2025  
Cash flows from operating activities:                
Net loss   $ (48.915 )   $ (24,466 )
Adjustments to reconcile net loss to net cash used in operating activities:                
Foreign exchange loss     —       45  
Depreciation of fixed assets     895       771  
Amortization of intangible assets     133       132  
Amortization of right-of-use assets     942       853  
Amortization of debt issuance costs     595       —  
Share-based compensation     9,488       4,603  
Change in fair value of financial instrument     5,690       2,956  
Loss on extinguishment of debt     1,186       838  
Loss on disposal of property and equipment     —       111  
Non-cash interest settled through share conversions     1,495       —  
Impairment of fixed assets     838       —  
Credit loss expense     933       100  
Inventory net realizable value adjustment     745       —  
Changes in operating assets and liabilities, net of acquisitions:                
Accounts receivable     (328 )      (395 )
Contract assets     498       (1,070 )
Inventory     (4,249 )     130  
Other assets     (2,323 )     1,347  
Accounts payable     3,799       (2,798 )
Accrued expenses     2,961       (515 )
Earn out payable     (150 )     (200 )
Right-of-use liabilities     (1,036 )     (773 )
Contract liabilities     6,029       (302 )
Net cash used in operating activities   $ (20,775 )   $ (18,634 )
Cash flows from investing activities:                
Purchases of property and equipment     (4,008 )     (505 )
Net cash used in investing activities   $ (4,008 )   $ (505 )
Cash flows from financing activities:                
Cash paid for tax withholding related to shares withheld   $ (807 )   $ (649 )
Payment of debt issuance costs     (524 )     —  
Proceeds from convertible notes     26,500       3,173  
Payment on convertible notes     (5,974 )     —  
Proceeds from issuance of common stock – At The Market offering, net of issuance costs     7,592       17,729  
Proceeds from issuance of common stock – Capital Raise, net of issuance costs     —       2,450  
Net cash provided by financing activities   $ 26,787     $ 22,703  
Net increase in cash, cash equivalents and restricted cash   $ 2,004     $ 3,564  
Cash, cash equivalents and restricted cash, beginning of year     6,869       3,305  
Cash, cash equivalents and restricted cash, end of year   $ 8,873     $ 6,869  
                 
Supplemental disclosure of noncash investing and financing activities:                
Common stock issued related to bonus and earnout payments   $ —     $ 630  
Common stock issued related to conversion of convertible debt     18,432       2,956  
Operating right of use asset obtained in exchange for operating lease liability   $ 1,276     $ —  



Posted on

U-Haul Holding Company Announces Twentieth Annual Virtual Analyst and Investor Meeting

U-Haul Holding Company Announces Twentieth Annual Virtual Analyst and Investor Meeting

RENO, Nev.–(BUSINESS WIRE)–
U-Haul Holding Company (NYSE: UHAL, UHAL.B), the parent company of U-Haul International, Inc., Oxford Life Insurance Company, Repwest Insurance Company and Amerco Real Estate Company will hold its twentieth annual virtual analyst and investor meeting on Thursday, August 20, 2026 at 11 a.m. Arizona time (2 p.m. Eastern Time).

To participate in our virtual meeting, please visit investors.uhaul.com and register under the “Latest Event” section on the homepage or through the “Events and Presentations” section of the website.

Questions for management can be emailed to [email protected] any time before the meeting or submitted live during the question-and-answer portion of the event.

About U-Haul Holding Company

U-Haul Holding Company is the parent company of U-Haul International, Inc., Oxford Life Insurance Company, Repwest Insurance Company and Amerco Real Estate Company. U-Haul is in the shared use business and was founded on the fundamental philosophy that the division of use and specialization of ownership is good for both U-Haul customers and the environment.

About U-Haul

Since 1945, U-Haul has been the No. 1 choice of do-it-yourself movers, with a network of more than 25,000 locations across all 50 states and 10 Canadian provinces. U-Haul Truck Share 24/7 offers secure access to U-Haul trucks every hour of every day through the customer dispatch option on their smartphones and our patented Live Verify technology. Our customers’ patronage has enabled the U-Haul fleet to grow to approximately 207,600 trucks, 136,500 trailers and 43,200 towing devices. U-Haul is the third largest self-storage operator in North America and offers 1,147,300 rentable storage units and 100.3 million square feet of self-storage space at owned and managed facilities. U-Haul is the largest retailer of propane in the U.S., and continues to be the largest installer of permanent trailer hitches in the automotive aftermarket industry. U-Haul has been recognized repeatedly as a leading “Best for Vets” employer and was recently named one of the 15 Healthiest Workplaces in America.

Sebastien Reyes

Director of Investor Relations

U-Haul Holding Company

(602) 263-6601

[email protected]

KEYWORDS: Nevada United States North America

INDUSTRY KEYWORDS: Commercial Building & Real Estate Construction & Property Trucking Insurance Aftermarket Automotive Transport Professional Services Other Automotive Fleet Management

MEDIA:

Logo
Logo
Posted on

Picard Medical Reports Second Quarter 2026 Financial Results

–
Revenue Increases 39% and Net Loss Decreases 16%-

Year-to-Date Revenue Increases 50%, with ~$0.9 Million in Gross Profit

TUCSON, Ariz., Aug. 19, 2026 (GLOBE NEWSWIRE) — Picard Medical, Inc. (NYSE American: PMI) (“Picard Medical” or the “Company”), parent company of SynCardia Systems, LLC (“SynCardia”), maker of the world’s first and only total artificial heart approved by both the U.S. FDA and Health Canada, today reported financial results for the second quarter ended June 30, 2026.

“We are encouraged by the progress reflected in our second-quarter results,” said Richard Fang, Interim Chief Executive Officer of Picard Medical. “Revenue growth and the improvement in gross profitability reflect progress in our core business. We are also advancing the development of our next-generation Emperor Total Artificial Heart platform and continuing to strengthen our operations. We are focused on continuing that progress, working to strengthen the Company’s financial position and investing thoughtfully in opportunities that can support long-term growth.”

Three Months Ended June 30, 2026 Financial Highlights

  • Revenue increased 39% to ~$3.0 million, compared with ~$2.1 million for the three months ended June 30, 2025. The increase was driven by an increase in U.S. sales of ~$0.8 million.
  • Gross profit was ~$0.6 million, compared with a gross loss of ~$0.1 million in the prior-year period, representing a gross margin of ~20.9% compared with a gross margin of ~(6.0)% in the prior-year period.
  • Net loss decreased 16% to ~$5.7 million, compared with a net loss of ~$6.7 million in the prior-year period.

Six Months Ended June 30, 2026 Financial Highlights

  • Revenue increased 50% to ~$4.1 million, compared with ~$2.7 million for the six months ended June 30, 2025. The increase was primarily driven by higher U.S. product sales, partially offset by lower European sales.
  • Gross profit was ~$0.9 million, compared with a gross loss of ~$0.5 million in the prior-year period, representing a gross margin of ~21.7% compared with a gross margin of ~(17.7)% in the prior-year period.
  • Net loss was ~$13.3 million, compared with a net loss of ~$12.3 million in the prior-year period. The increase primarily reflects higher research and development and selling, general and administrative expenses, partially offset by lower total other expenses.

Business and Strategic Highlights

SynCardia: U.S. sales continued to drive growth in the Company’s core business during the first half of 2026. The Company continues to focus on supporting customer requirements and strengthening commercial execution.

Emperor Total Artificial Heart: The Company continued preclinical development of its next-generation artificial heart platform during the quarter, including the successful completion of a series of acute in vivo implant studies evaluating the latest iteration of the Emperor Total Artificial Heart (“Emperor TAH”). The Company also presented new in vivo Emperor data at the 2026 Annual Conference of the American Society for Artificial Internal Organs (“ASAIO 2026”).

Following quarter-end, the Company publicly presented the integrated architecture of the Emperor TAH platform for the first time at the 48th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (IEEE EMBC 2026). The presentation provided the biomedical engineering community with a detailed view of the Emperor TAH platform and its electromechanical drive architecture. The Company believes the presented architecture has the potential to serve as a platform for a first-of-a-kind fully implantable total artificial heart.

Clinical Research: The Company also presented new clinical outcomes research involving patients supported with the SynCardia Total Artificial Heart at ASAIO 2026.

Manufacturing: The Company continued initiatives focused on improving manufacturing efficiency, quality control and supply-chain resilience to support the SynCardia business and future growth.

Corporate and Financial Update

NYSE American accepted the Company’s compliance plan in July 2026, providing additional time for the Company to regain compliance with applicable listing standards.

Following stockholder approval at the Annual Meeting, the Company completed a 1-for-50 reverse stock split effective July 31, 2026, as part of its efforts to support continued compliance with NYSE American listing standards.

The Company continues to evaluate additional financing opportunities to support ongoing operations and future growth. Management remains focused on sales, improving operating performance and strengthening the Company’s financial position.

Looking Ahead

Picard Medical remains focused on growing its business, improving operating and financial performance, advancing next-generation technology and using capital thoughtfully.

“We recognize the work that remains ahead of us,” Fang said. “Our focus is on disciplined execution and building on the progress we are seeing across the business while continuing to advance our long-term technology and commercial objectives.”

About Picard Medical and SynCardia

Picard Medical, Inc. is the parent company of SynCardia Systems, LLC (“SynCardia”), the Tucson, Arizona–based leader with the only commercially available total artificial heart technology for patients with end-stage heart failure. SynCardia develops, manufactures, and commercializes the SynCardia Total Artificial Heart (“STAH”), an implantable system that assumes the full functions of a failing or failed human heart. It is the first artificial heart approved by both the FDA and Health Canada, and it remains the only commercially available artificial heart in the United States and Canada. With more than 2,100 implants performed at hospitals across 27 countries, the STAH is the most widely used and extensively studied artificial heart in the world. For additional information about Picard Medical, please visit www.picardmedical.com or review the Company’s filings with the U.S. Securities and Exchange Commission (the “SEC”) at www.sec.gov.

Forward-Looking Statements

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are based on management’s current expectations, assumptions and beliefs that involve risks and uncertainties. Forward-looking statements are statements that are not historical facts. Forward-looking statements can often be identified by words such as “continue,” “remain,” “advance,” “focus,” “potential,” “believe” and similar expressions, and variations or negatives of these words. These statements include, but are not limited to, statements regarding the Company’s focus on strengthening its financial position and investing in opportunities to support long-term growth; the continued advancement of preclinical development of the Emperor TAH platform, including the potential for the Emperor platform’s architecture to serve as a platform for a first-of-a-kind fully implantable total artificial heart; initiatives to improve manufacturing efficiency, quality control and supply-chain resilience; the Company’s evaluation of additional financing opportunities to support ongoing operations and future growth; the Company’s focus on growing its business and improving operating and financial performance; the Company’s ability to implement its compliance plan and regain compliance with NYSE American listing standards within the time provided. Such forward-looking statements are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. The Company expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based. Additional information about the Company, including risk factors that may affect the Company’s business, financial condition, and results of operations, is contained in the Company’s filings with the SEC, including the Company’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, which are available free of charge on the SEC’s website at http://www.sec.gov and on the Company’s investor relations website at https://picardmedical.com/.

Contact:

Investors

Picard Medical, Inc./SynCardia Systems, LLC

[email protected]

Brittany Lanza

[email protected]



Posted on

Northrop Grumman Board Declares Quarterly Dividend

FALLS CHURCH, Va., Aug. 19, 2026 (GLOBE NEWSWIRE) — The board of directors of Northrop Grumman Corporation (NYSE: NOC) declared a quarterly dividend of $2.47 per share on Northrop Grumman common stock, payable September 16, 2026, to shareholders of record as of the close of business August 31, 2026. Northrop Grumman continues to execute a disciplined capital allocation strategy that prioritizes investments in the manufacturing capabilities and capacity needed to deliver differentiating technologies quickly for our customers.

Northrop Grumman is a leading global aerospace and defense technology company. Our pioneering solutions equip our customers with the capabilities they need to connect and protect the world, and push the boundaries of human exploration across the universe. Driven by a shared purpose to solve our customers’ toughest problems, our employees define possible every day.

Contact: 
News Bureau
[email protected]

Randy Sinclair (Investors)
[email protected]